Related Experiment Video
Updated: Jun 20, 2026
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Immunogenetic modulation of endothelial inflammation by the LIPG -384A/C promoter variant influences COVID-19
HariOm Singh1, Aishwarya Nair1, Meenakshi Bhattacharya2
1BSL-4, ICMR-National Institute of Virology, Pune, India.
Insights
A specific gene variant, LIPG -384A/C, is linked to increased risk and severity of COVID-19. This genetic factor influences immune responses and inflammation, impacting endothelial function in severe cases.
Area of Science:
- Immunogenetics
- Vascular Biology
- COVID-19 Pathogenesis
Background:
- Severe COVID-19 involves immune dysregulation and endothelial injury, leading to inflammation.
- Endothelial lipase (EL), encoded by LIPG, impacts inflammatory pathways and immune-endothelial interactions.
- The role of LIPG promoter variants in COVID-19-related endothelial dysfunction is unclear.
Purpose of the Study:
- To investigate the association between LIPG promoter variants and COVID-19 severity.
- To explore the impact of these variants on inflammatory markers and endothelial function.
- To elucidate the immunogenetic contribution of LIPG to COVID-19 pathogenesis.
Main Methods:
- Case-control study with 151 COVID-19 patients and 152 controls.
- Genotyping of the LIPG -384A/C promoter variant using PCR-based allelic discrimination.
- Analysis of associations with disease severity, inflammatory markers (ferritin, leukocyte count), and in silico transcription factor binding.
Main Results:
- The LIPG -384C allele was significantly associated with increased risk of severe COVID-19.
- Individuals with the risk allele showed higher ferritin levels and leukocyte counts, indicating heightened immune activation.
- In silico analysis confirmed the variant alters transcription factor binding sites related to inflammation and immune response.
Conclusions:
- The LIPG -384A/C promoter variant is a novel immunogenetic determinant of COVID-19 severity.
- This variant may mediate disease progression by modulating immune-driven endothelial inflammation.
- Host immunogenetics at the immune-endothelial interface critically influence COVID-19 outcomes.
Background:
Severe COVID-19 is characterized by dysregulated host immune responses and immune-mediated endothelial injury, culminating in microvascular dysfunction and systemic inflammation. Endothelial lipase (EL), encoded by the LIPG gene, regulates endothelial lipid metabolism and inflammatory signaling pathways that influence immune-endothelial interactions. Despite its relevance to vascular immunopathology, the immunogenetic contribution of LIPG promoter variants to immune-driven endothelial dysfunction in COVID-19 remains poorly defined.
Methods:
We performed a case-control study including 151 RT-PCR-confirmed COVID-19 patients stratified according to disease severity and 152 healthy controls. Genotyping of the LIPG -384A/C (rs3813082) promoter variant was carried out using polymerase chain reaction-based allelic discrimination. Associations between genotype and disease severity were evaluated alongside inflammatory and immune-related parameters, including serum ferritin and total leukocyte count. In silico analyses were conducted to assess the impact of the promoter variant on transcription factor binding sites involved in immune and inflammatory regulation.
Results:
The LIPG -384C allele was significantly associated with an increased risk of severe COVID-19 and a heightened inflammatory profile. Individuals carrying the risk allele demonstrated significantly elevated ferritin levels and leukocyte counts, indicative of amplified systemic immune activation. Computational functional annotation revealed that the -384A/C substitution modifies transcription factor binding motifs linked to inflammatory and immune-responsive pathways, supporting a mechanistic role for this variant in regulating endothelial immune signaling.
Conclusion:
This study identifies the LIPG -384A/C promoter variant as a novel immunogenetic determinant of COVID-19 severity, potentially mediating disease progression through modulation of immune-driven endothelial inflammation. Our findings underscore the critical role of host immunogenetic factors at the immune-endothelial interface in shaping inflammatory responses and clinical outcomes in COVID-19, providing insight into vascular immunopathology and host susceptibility.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu